A Phase I, Randomized, Parallel-Controlled, Single and Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects
Latest Information Update: 13 Mar 2025
At a glance
- Drugs CX-2101-A (Primary)
- Indications COVID-19 pneumonia
- Focus Adverse reactions
- 13 Mar 2025 New trial record